Skip to main content
Fig. 3 | Diabetology & Metabolic Syndrome

Fig. 3

From: Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent

Fig. 3

a Changes in FPG during the 12-week treatment with vildagliptin, sitagliptin, or linagliptin. The FPG levels in the three groups showed no difference at week 0. The FPG in the vildagliptin group was the lowest at week 6 (*P < 0.05). The FPG levels in the vildagliptin and linagliptin groups were lower than in the sitagliptin group at week 12 (*P < 0.05). b Changes in PPG during the 12 weeks in the vildagliptin, sitagliptin, or linagliptin group. The PPG levels were not significantly different between the groups. The PPG levels in the vildagliptin and linagliptin groups were lower than in the sitagliptin group at week 6 (*P < 0.05). The PPG in the linagliptin group was the lowest one, and the PPG in the vildagliptin group was lower than in the sitagliptin group at week 12 (*P < 0.05)

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us